INVA or MRK: Which Is the Better Value Stock Right Now?
Innoviva, Inc. INVA
$19.07
▲ +0.37%
(+$0.07)
Open
$19.29
Prev Close
$19.00
Day Range
$18.82 – $20.11
52W Range
$18.85 – $25.15
Market Cap
$1.38B
P/E (TTM)
6.99
Beta
0.40
EPS (TTM)
$1.96
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-10-05 |
| Shares Out. | 72,250,000 |
| Website | inva.com/ ↗ |
| Phone | 13026587581 |
| Employees | 159 |
| Revenue | $106.1M |
| Gross Profit | $84.4M |
| Net Income | -$73.9M |
| Free Cash Flow | $182.5M |
| Total Assets | $1.54B |
| Total Liabilities | $400.4M |
| Equity | $1.14B |
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva, Inc. is a publicly traded company under the ticker symbol INVA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-11-01)
📰 Latest News for INVA
Oppenheimer Maintains Outperform on Innoviva, Lowers Price Target to $34
Innoviva (INVA) Tops Q3 Earnings Estimates
Innoviva: Q3 Earnings Snapshot
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates
Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue Estimates